Patents by Inventor Lars Torup

Lars Torup has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Nalmefene for reduction of alcohol consumption in specific target populations
    Patent number: 10034874
    Abstract: The present invention relates to nalmefene for use in the reduction of alcohol consumption in a patient with alcohol dependence who has a high drinking risk level. The present invention also relates to nalmefene for use in the reduction of alcohol consumption in a patient with alcohol dependence who maintains a high DRL after an observation period following initial assessment.
    Type: Grant
    Filed: March 22, 2017
    Date of Patent: July 31, 2018
    Assignee: H. Lundbeck A/S
    Inventors: Lars Torup, Afsaneh Abbariki, Anna Bladstrom, Christine Persson, Didier Meulien, Per Sorensen, Thomas Jon Jensen, Jette Buch Ostergaard
  • NALMEFENE FOR REDUCTION OF ALCOHOL CONSUMPTION IN SPECIFIC TARGET POPULATIONS
    Publication number: 20180028526
    Abstract: The present invention relates to nalmefene for use in the reduction of alcohol consumption in a patient with alcohol dependence who has a high drinking risk level. The present invention also relates to nalmefene for use in the reduction of alcohol consumption in a patient with alcohol dependence who maintains a high DRL after an observation period following initial assessment.
    Type: Application
    Filed: March 22, 2017
    Publication date: February 1, 2018
    Inventors: Lars TORUP, Afsaneh ABBARIKI, Anna BLADSTROM, Christine PERSSON, Didier MEULIEN, Per SORENSEN, Thomas Jon JENSEN, Jette Buch OSTERGAARD
  • Nalmefene for reduction of alcohol consumption in specific target populations
    Patent number: 9642849
    Abstract: The present invention relates to nalmefene for use in the reduction of alcohol consumption in a patient with alcohol dependence who has a high drinking risk level. The present invention also relates to nalmefene for use in the reduction of alcohol consumption in a patient with alcohol dependence who maintains a high DRL after an observation period following initial assessment.
    Type: Grant
    Filed: April 7, 2016
    Date of Patent: May 9, 2017
    Assignee: H. LUNDBECK A/S
    Inventors: Lars Torup, Afsaneh Abbariki, Anna Bladström, Christine Persson, Didier Meulien, Per Sørensen, Thomas Jon Jensen, Jette Buch Østergaard
  • Nalmefene for Reduction of Alcohol Consumption in Specific Target Populations
    Publication number: 20160375007
    Abstract: The present invention relates to nalmefene for use in the reduction of alcohol consumption in a patient with alcohol dependence who has a high drinking risk level. The present invention also relates to nalmefene for use in the reduction of alcohol consumption in a patient with alcohol dependence who maintains a high DRL after an observation period following initial assessment.
    Type: Application
    Filed: April 7, 2016
    Publication date: December 29, 2016
    Applicant: H. Lundbeck A/S
    Inventors: Lars Torup, Afsaneh Abbariki, Anna Bladström, Christine Persson, Didier Meulien, Per Sørensen, Thomas Jon Jensen, Jette Buch Østergaard
  • Nalmefene for Treatment of Patients with Anxiety Disorder
    Publication number: 20160058754
    Abstract: The present invention relates to nalmefene for use in the treatment of anxiety disorders. The present invention further relates to nalmefene for use in the treatment of patients with alcohol dependence who have a co-morbid anxiety disorder. The invention further relates to nalmefene for use in the treatment of an anxiety disorder in said patients.
    Type: Application
    Filed: April 16, 2014
    Publication date: March 3, 2016
    Applicant: H. Lundbeck A/S
    Inventors: Didier Meulien, David Gruhn, Lars Torup, Björn Steiniger-Brach
  • Nalmefene for Treatment of Patients with Mood Disorder
    Publication number: 20160058753
    Abstract: The present invention relates to nalmefene for use in the treatment of mood disorders. The present invention further relates to nalmefene for use in the treatment of patients with alcohol dependence who have a co-morbid mood disorder. The invention further relates to nalmefene for use in the reduction of alcohol consumption in said patients. The invention further relates to nalmefene for use in the treatment of a mood disorder in said patients.
    Type: Application
    Filed: April 16, 2014
    Publication date: March 3, 2016
    Applicant: H. Lundbeck A/S
    Inventors: Didier Meulien, David Gruhn, Lars Torup, Björn Steiniger-Brach
  • Nalmefene for reduction of alcohol consumption in specific target populations
    Publication number: 20140005217
    Abstract: The present invention relates to nalmefene for use in the reduction of alcohol consumption in a patient with alcohol dependence who has a high drinking risk level. The present invention also relates to nalmefene for use in the reduction of alcohol consumption in a patient with alcohol dependence who maintains a high DRL after an observation period following initial assessment.
    Type: Application
    Filed: June 26, 2013
    Publication date: January 2, 2014
    Inventors: Lars Torup, Afsaneh Abbariki, Anna Bladstrom, Christine Persson, Didier Meulien, Per Sorensen, Thomas Jon Jensen, Jette Buch Ostergaard
  • Nalmefene for reduction of alcohol consumption in specific target populations
    Publication number: 20140005216
    Abstract: The present invention relates to nalmefene for use in the reduction of alcohol consumption in a patient with alcohol dependence who has a high drinking risk level. The present invention also relates to nalmefene for use in the reduction of alcohol consumption in a patient with alcohol dependence who maintains at least medium DRL after an observation period following initial assessment.
    Type: Application
    Filed: June 26, 2013
    Publication date: January 2, 2014
    Inventors: Lars Torup, Afsaneh Abbariki, Anna Bladström, Christine Persson, Didier Meulien, Per Sørensen, Thomas Jon Jensen, Jette Buch Østergaard
  • TREATMENT OF DYSKINESIA RELATED DISORDERS
    Publication number: 20120108624
    Abstract: Disclosed herein are methods of treating Parkinsons disease while maintaining a low dyskinesia induction profile and methods of reversing dyskinesias comprising administering a therapeutically effective amount of a compound of the invention. The present invention further relates to uses and pharmaceutical compositions of said compounds in the manufacture of medicaments in treating the same.
    Type: Application
    Filed: February 26, 2010
    Publication date: May 3, 2012
    Inventors: Håkan Wikström, Morten Jørgensen, Niels Mork, Jennifer Larsen, Lars Torup, Benny Bang-Andersen
  • METHODS OF ADMINISTERING (4AR,10AR)-1-N-PROPYL-1,2,3,4,4A,5,10,10A-OCTAHYDROBENZO [G] QUINOLINE-6,7-DIOL AND RELATED COMPOUNDS ACROSS THE ORAL MUCOSA, THE NASAL MUCOSA OR THE SKIN AND PHARMACEUTICAL COMPOSITIONS THEREOF
    Publication number: 20120077836
    Abstract: Disclosed are pharmaceutical compositions and methods for the administration of (4aR,10aR)-1-n-propyl-1,2,3,4,4a,5,10,10a-octahydro-benzo[g]quinoline-6,7-diol or a pharmaceutically acceptable salt thereof and related compounds for the treatment of neurological disorder such as Parkinson's disease and restless leg syndrome.
    Type: Application
    Filed: February 26, 2010
    Publication date: March 29, 2012
    Applicant: H. LUNDBECK A/S
    Inventors: Håkan Wikström, Morten Jorgensen, Niels Mork, Jennifer Larsen, Benny Bang-Andersen, Thomas Nikolaj Sager, Ask Püschl, Lars Torup